Ensysce Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Ensysce Biosciences generated cash of -$10,779,982, which is more than the previous year. Cash used in financing activities reached the amount of $8,755,884 last year. Net change in cash is therefore -$2,024,098.
Cash Flow
| 2017 | -251.83K | -200M | 202.34M |
|---|---|---|---|
| 2018 | -1.23M | 838.58K | -32K |
| 2019 | 10.99M | -566.28K | -11.02M |
| 2020 | -1.24M | 183.40M | 1.10M |
| 2021 | -8.24M | 0 | 20.31M |
| 2022 | -17.88M | 4.5K | 8.76M |
| 2023 | -10.77M | 0 | 8.75M |
ENSC Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 3.14M | 12.26M | 194.21K | 341.53K | 1.65M | 2.09M | 0 |
Operating activities | |||||||
Net income | -10.62M | -24.20M | -29.14M | -160.87K | 365.95K | -1.34M | -31.19K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 326.15K | 0 | 151 | 201 | 201 | 0 | 0 |
Stock-based compensation expense | 879.16K | 1.07M | 121.76K | 178.67K | 6.03M | 0 | 0 |
| Deferred income tax benefit | 879.16K | 1.07M | 121.76K | 178.67K | 6.03M | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 179.26K | 164.9K | -441.72K | 173.55K | -173.55K | -170.53K | 0 |
Inventories | 0 | -164.9K | 441.72K | -173.55K | -2.16M | 0 | 0 |
Accounts payable | -1.23M | 2.64M | -1.42M | 1.18M | 2.34M | 317.28K | 111.96K |
Cash generated by operating activities | -10.77M | -17.88M | -8.24M | -1.24M | 10.99M | -1.23M | -251.83K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -566.28K | 0 | -200M |
Investments In Property Plant And Equipment | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 4.5K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 0 | 4.5K | 0 | 183.40M | -566.28K | 838.58K | -200M |
Financing activities | |||||||
Common Stock Issued | 9.05M | 3.78M | 6.62M | 0 | -8.64K | -32K | 202.34M |
Payments for dividends | 0 | -913.20K | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 803.14B | 0 | -11.58M | 0 | 0 |
Repayments of term debt | 605.42K | 6.12M | -467.77K | -1.1M | 400K | 0 | 0 |
Cash used in financing activities | 8.75M | 8.76M | 20.31M | 1.10M | -11.02M | -32K | 202.34M |
Net Change In Cash | -2.02M | -9.11M | 12.07M | -147.32K | -597.24K | -431.67K | 2.09M |
Cash at end of period | 1.12M | 3.14M | 12.26M | 194.21K | 1.06M | 1.65M | 2.09M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |